Literature DB >> 12105243

Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks.

Catherine Dodé1, Bouke P C Hazenberg, Christophe Pêcheux, Daniel Cattan, Bruno Moulin, Anne Barthélémy, Marie-Claire Gubler, Marc Delpech, Gilles Grateau.   

Abstract

BACKGROUND: Among hereditary fevers characterized by recurrent attacks of fever and organ localized inflammation, familial Mediterranean fever (FMF), and tumour necrosis factor receptor superfamily 1A (TNFRSF1A) receptor associated periodic syndrome (TRAPS) are diseases with identified genes that can be associated with renal amyloidosis of the AA type. In this study we have characterized FMF and TRAPS genotypes in 38 unrelated patients suffering from amyloidosis AA and recurrent inflammatory attacks.
METHODS: Mutations of the MEFV and TNFRSF1A genes, responsible respectively for FMF and TRAPS, were searched for by amplifying, using polymerase chain reaction (PCR), genomic DNA, and direct sequencing.
RESULTS: Twenty-seven patients (71%) carried mutations in MEFV (22 patients with two mutations, two patients with a single mutation) or TNFRSF1A genes (three patients). Patients with MEFV mutations belonged to the classical at-risk ethnic group for FMF: Sephardic Jews, Turks, Armenians, and Arabs from the Maghreb. The main genotype encountered was M694V/M694V (19/22), one Turkish patient was M680I/M680I, and two Arab patients from the Maghreb were M694I/M694I. We found three Caucasian patients with the C55S, C70Y, R92Q mutations in the TNFRSF1A gene.
CONCLUSIONS: In this series we observed that FMF is the main cause of AA amyloidosis in Sephardic Jews and Turks. MEFV and TNFRSF1A mutations were found in only 6 of 14 Arab patients from the Maghreb. We found three families (one Caucasian and two from Maghreb) with AA amyloidosis without MEFV or TNFRSF1A mutations, suggesting that other genetic cause(s) exist(s). The characterization of mutations in MEFV and TNFRSF1A is important for the therapeutic behaviour of AA amyloidosis associated with inherited recurrent fever.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12105243     DOI: 10.1093/ndt/17.7.1212

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  Intrafamilial segregation analysis of the p.E148Q MEFV allele in familial Mediterranean fever.

Authors:  D O Tchernitchko; M Gérard-Blanluet; M Legendre; C Cazeneuve; G Grateau; S Amselem
Journal:  Ann Rheum Dis       Date:  2006-01-26       Impact factor: 19.103

2.  "Periodic fever" without fever: two cases of non-febrile TRAPS with mutations in the TNFRSF1A gene presenting with episodes of inflammation or monosymptomatic amyloidosis.

Authors:  T Kallinich; D Haffner; B Rudolph; R Schindler; S Canaan-Kühl; R Keitzer; G R Burmester; A Roesen-Wolff; J Roesler
Journal:  Ann Rheum Dis       Date:  2005-11-24       Impact factor: 19.103

3.  Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour.

Authors:  Ian Todd; Paul M Radford; Kelly-Ann Draper-Morgan; Richard McIntosh; Susan Bainbridge; Peter Dickinson; Lama Jamhawi; Marios Sansaridis; Mary L Huggins; Patrick J Tighe; Richard J Powell
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

4.  Gastric changes following colchicine therapy in patients with FMF.

Authors:  Wael Ismail Al-Daraji; Riham M W Al-Mahmoud; Mohammed Ilyas
Journal:  Dig Dis Sci       Date:  2007-12-15       Impact factor: 3.199

5.  Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap).

Authors:  Leigh D Church; Sinisa Savic; Michael F McDermott
Journal:  Biologics       Date:  2008-12

6.  TNF receptor-associated periodic syndrome (TRAPS): description of a novel TNFRSF1A mutation and response to etanercept.

Authors:  Adriana A Jesus; João B Oliveira; Ivona Aksentijevich; Erika Fujihira; Magda M S Carneiro-Sampaio; Alberto J S Duarte; Clovis A A Silva
Journal:  Eur J Pediatr       Date:  2008-04-12       Impact factor: 3.860

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.